課題の克服とソリューションの探求

1月12日〜13日

治療と診断に必要とされるタンパク質の大半は、既存のホストでの発現が難しく、フォールディングや溶解性、グリコシル化などの面で問題を抱えているうえ、ホストに対して毒性を有するものすらあります。この部会では、タンパク質科学分野における最新の成果が紹介され、これらの課題を克服するための識見やソリューションが示されます。

基調プレゼンテーション

Protein Expression in Drug Discovery – New Challenges, New Solutions

Lorenz Mayr, Ph.D., Executive Director, CPC/EPP, Novartis Pharma AG

Enhanced Glycoprotein Production in HEK-293 Cells Expressing Pyruvate Carboxylase

Yves Durocher, Ph.D., Chemical Engineering, École Polytechnique de Montréal

溶解性、フォールディング、グリコシル化の問題に対処するためのソリューション

Expression of Soluble Proteins by Linkage with Acidic Tags

Richard Discipio, Ph.D., Research Scientist, Torrey Pines Institute for Molecular Studies

Measurement of Protein Unfolding/Refolding Kinetics and Structural Characterization of Hidden Intermediates by NMR Relaxation Dispersion

Derrick Meinhold, Ph.D., Research Associate, Department of Molecular Biology and Skaggs Institute of Chemical Biology, The Scripps Research Institute

Effects of Cell Culture Conditions on Antibody N-Linked Glycosylation—What Affects High Mannose 5 Glycoform?

Efren Pacis, Biologics Pharma Technical Development, Genentech, Inc.

膜タンパク質にまつわる問題の解決

Restrained Expression: A Method to Overproduce Toxic Membrane Proteins by Exploiting Operator-Repressor Interactions

Dinesh A. Yernool, Ph.D., Assistant Professor, Department of Biological Sciences, Purdue University

Reprogramming Chaperone Pathways to Improve Membrane Protein Expression in Escherichia coli

Francois Baneyx, Ph.D., Professor, Chemical Engineering, University of Washington, Seattle

タンパク質凝集のキャラクタリゼーションに対応する解析法の課題と進歩

Aggregates and Their Analysis: Some Perspectives and Lessons from Working with 100+ Products

John Philo, Ph.D., Vice President, Director of Biophysical Chemistry, Alliance Protein Laboratories

Addressing New Analytical Challenges in Protein Formulation Development

Speaker to be Announced

Characterization of Submicron Particle Distributions in Biologics Formulations

Flaviu Gruia, Ph.D., Scientist, Analytical Biochemistry, MedImmune

Characterization of Sub-Visible Particles in Therapeutic Protein Formulations

Tobias Frommknecht, Ph.D., Formulation Scientist, pRED, Hoffmann-La Roche Ltd